MG98, a Second-Generation DNMT1 Inhibitor, in the Treatment of Advanced Renal Cell Carcinoma

REFERENCES

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Drabkin HA. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 2007;12:1404–1415.
   PubMed Web of Science ®Google Scholar
• Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993;20:303–321.
   PubMed Web of Science ®Google Scholar
• Bleumer I, Oosterwijk E, De Mulder P, Mulders PF. Immunotherapy for renal cell carcinoma. Eur Urol 2003;44:65–75.
   PubMed Web of Science ®Google Scholar
• Dutcher JP, Szczylik C, Tannir N, Benedetto P, Ruff P, Hsu A, Berkenblit A, Thiele A, Strahs A, Feingold J. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 2007;25(18S):5033.
   Google Scholar
• Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009; ebpub 20 Mar.
   PubMedGoogle Scholar
• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J Clin Oncol 2007;25(18S):241S.
   PubMedGoogle Scholar
• Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 2007;356:125–134.
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New J Med 2003;349:427–434.
   PubMed Web of Science ®Google Scholar
• Escudier B, Koralewski P, Pluzanska A, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Moore N. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 2007;25(18S):3.
   PubMedGoogle Scholar
• Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, Epstein RJ, Baker KL, McCann L, Crofts T, Pandite L, Figlin RA. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;28(3):475–480.
   PubMed Web of Science ®Google Scholar
• Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. New Engl J Med 2003;349:2042–2054.
   PubMed Web of Science ®Google Scholar
• Szyf M. The DNA methylation machinery as a target for anticancer therapy. Pharmacol Ther 1996;70:1–37.
   PubMed Web of Science ®Google Scholar
• MacLeod RA, Rouleau J, Szyf M. Regulation of DNA methylation status by the ras signaling pathway. J Biol Chem 1995;270:11327–11337.
   PubMed Web of Science ®Google Scholar
• Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, MacLeod AR. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 2003;33:61–65.
   PubMed Web of Science ®Google Scholar
• Kautiainen TL, Jones PA. DNA methyltransferase levels in tumorigenic and nontumorigenic cells in culture. J Biol Chem 1996;261:1594–1598.
   Google Scholar
• Szyf M. DNA methylation properties: consequences for pharmacology. Trends Pharmacol Sci 1994;15:233–238.
   PubMed Web of Science ®Google Scholar
• Battaglia C, Uzzo RG, Dulaimi E, Ibanez de Caceres I, Krassenstein R, Al-Saleem T, Greenberg RE, Cairns P. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res 2003;63:8695–8699.
   PubMed Web of Science ®Google Scholar
• Yeivin A, Razin A. Gene methylation patterns and expression. EXS 1993;64:523–568.
   PubMedGoogle Scholar
• Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB, Vogelstein B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002;416:552–556.
   PubMed Web of Science ®Google Scholar
• Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG, Kinzler KW, Vogelstein B, Baylin SB, Schuebel KE. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 2000;404:1003–1007.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Iyer RP. Perspectives in antisense therapeutics. Pharmacol Ther 1997;76:151–160.
   PubMed Web of Science ®Google Scholar
• Frederic J. Reu, Mark W. Fox, Mamta Chawla-Sarkar, Normand Beaulieu, Douglas W. Leaman, A. Robert Macleod, Ernest C. Borden. Genes involved in sensitization of renal cancer cells to interferon-induced apoptosis after selective depletion of DNA methyltransferase-1 by antisense oligonucleotide (MG98). Proc Amer Assoc Cancer Res. Volume 45, 2004 . Abstract #1609.
   Google Scholar
• Reu FJ, Beaulieu N, Mama CS, Macleod RA, Borden EC. Selective depletion of DNA methyltransferase-1 by antisense (MG98) sensitized renal cancer cells to interferon-induced apoptosis. Clin Cancer Res 2003;9 (December Suppl. 16): Abstract #167.
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–216.
   PubMed Web of Science ®Google Scholar
• Battagli C, Uzzo RG, Dulaimi E, Ibanez de Caceres I, Krassenstein R, Al-Saleem T, Greenberg RE, Cairns P. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer res 2003;63:8695–8699.
   PubMed Web of Science ®Google Scholar
• Alleman WG, Tabios RL, Chandramouli GV, Aprelikova ON, Torres-Cabala C, Mendoza A, Rogers C, Sopko NA, Linehan WM, Vasselli JR. The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'deoxycytidine. Clin Cancer Res 2004;10:7011–7021.
   PubMed Web of Science ®Google Scholar
• Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumour spuppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998;22:200–209.
   PubMed Web of Science ®Google Scholar
• Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;9700–9704.
   PubMed Web of Science ®Google Scholar
• Arai E, Kanai Y, Ushijima S, Fujimoto H, Mukai K, Hirohashi S. Regional DNA hypermethylation and DNA methyltranserase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. Int J Cancer 2006;119:288–296.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Iyer RP. Perspectives in antisense therapeutics. Pharmacol Ther 1997;76:151–160.
   PubMed Web of Science ®Google Scholar